Literature DB >> 6378603

The antilipolytic, insulin-like effect of growth hormone is caused by a net decrease of hormone-sensitive lipase phosphorylation.

P Björgell, S Rosberg, O Isaksson, P Belfrage.   

Abstract

The mechanism of the antilipolytic effect of GH and the cause of refractoriness to its own action was studied in isolated rat adipocytes. Human GH rapidly inhibited catecholamine-stimulated lipolysis rate, with a time course similar to that of insulin, but only in cells which had been preincubated in the absence of GH for 2-3 h. Half-maximal inhibition was obtained with a GH concentration of 100 ng/ml. Parallel determinations of the lipolysis rate (with a pH-stat titration technique) and the extent of phosphorylation of hormone-sensitive lipase, the rate-controlling enzyme in adipose tissue lipolysis, were made. The extent of lipase phosphorylation, 1.7-fold enhanced by previous noradrenaline stimulation, was rapidly reversed by addition of GH, and the decrease was followed by a parallel decrease in the lipolysis rate. The time course and magnitude of these effects was similar to those obtained with exposure of the cells to insulin, indicating that the antilipolytic effect of both hormones was exerted through the same mechanism: a net dephosphorylation of the hormone-sensitive lipase. To study the refractoriness of the fat cells to the action of GH (which was not found with insulin) adipocytes were prepared from hypophysectomized rats 24 h after surgery. With such cells no preincubation was required to obtain the effects of GH on the lipolysis rate and extent of hormone-sensitive lipase phosphorylation. The effects of GH on both of the parameters studied were similar to those obtained in nonhypophysectomized rats. These results suggest that the refractoriness of the fat cells to GH may be explained by a functional inhibition at a site(s) in the series of metabolic events initiated by GH action, which precedes the activation of the hormone-sensitive lipase.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6378603     DOI: 10.1210/endo-115-3-1151

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Growth hormone increases phosphoinositide turnover in rat adipocytes that are sensitive to the insulin-like action of the hormone.

Authors:  H Eriksson; R Sundler; J Donnér
Journal:  Mol Cell Biochem       Date:  1990-09-21       Impact factor: 3.396

2.  The insulin-like effect of growth hormone on insulin-like growth factor II receptors is opposed by cyclic AMP. Evidence for a common post-receptor pathway for growth hormone and insulin action.

Authors:  J Eriksson; I Gause-Nilsson; P Lönnroth; U Smith
Journal:  Biochem J       Date:  1990-06-01       Impact factor: 3.857

3.  Specific inhibition of the cGMP-inhibited cAMP phosphodiesterase blocks the insulin-like antilipolytic effect of growth hormone in rat adipocytes.

Authors:  H Eriksson; H Tornqvist
Journal:  Mol Cell Biochem       Date:  1997-04       Impact factor: 3.396

4.  Characterization of the insulin-antagonistic effect of growth hormone in man.

Authors:  J Fowelin; S Attvall; H von Schenck; U Smith; I Lager
Journal:  Diabetologia       Date:  1991-07       Impact factor: 10.122

5.  Growth hormone stimulates c-fos gene expression by means of protein kinase C without increasing inositol lipid turnover.

Authors:  A Doglio; C Dani; P Grimaldi; G Ailhaud
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

6.  Regulation of insulin-like growth factor II receptors by growth hormone and insulin in rat adipocytes.

Authors:  P Lönnroth; K Assmundsson; S Edén; G Enberg; I Gause; K Hall; U Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

Review 7.  Insulin signaling in health and disease.

Authors:  Alan R Saltiel
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

8.  Different thresholds of tissue-specific dose-responses to growth hormone in short prepubertal children.

Authors:  Ralph Decker; Anders Nygren; Berit Kriström; Andreas Fm Nierop; Jan Gustafsson; Kerstin Albertsson-Wikland; Jovanna Dahlgren
Journal:  BMC Endocr Disord       Date:  2012-11-01       Impact factor: 2.763

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.